30May 2023
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial

Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial

Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, was evaluated for the treatment of chorea associated with Huntington's disease. The phase 3 clinical trial, KINECT-HD, involved 128 participants with genetically confirmed Huntington's disease and chorea. They were randomly assigned to receive either valbenazine or a placebo for 12 weeks. The primary endpoint was the change in chorea severity measured by the Unified Huntington's Disease Rating Scale (UHDRS). Valbenazine demonstrated a significant improvement in chorea compared to placebo. The most common adverse event was somnolence. No clinically important changes in vital signs, electrocardiograms, or laboratory tests were observed. Further research is needed to establish the long-term safety and efficacy of valbenazine for Huntington's disease-related chorea.

  • #neurology

Like

Save

Share